The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function

Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hebner, Christy M., Han, Bin, Brendza, Katherine M., Nash, Michelle, Sulfab, Maisoun, Tian, Yang, Hung, Magdeleine, Fung, Wanchi, Vivian, Randall W., Trenkle, James, Taylor, James, Bjornson, Kyla, Bondy, Steven, Liu, Xiaohong, Link, John, Neyts, Johan, Sakowicz, Roman, Zhong, Weidong, Tang, Hengli, Schmitz, Uli
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2012
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3374789/
https://ncbi.nlm.nih.gov/pubmed/22720059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0039163
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi